Policy / Pricing FDA Reminds More Than 2,200 Sponsors and Researchers to Disclose Trial Results FDAThe U.S.Policy / PricingRead full story pharminent April 13, 2026 (Last updated: April 14, 2026) FDA The U.S. Policy / PricingRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: USP adds Tamiflu, Trulicity to vulnerable list as upstream analysis reshapes supply concernsNext: Allogene data suggest ‘off-the-shelf’ CAR-T could delay relapse in lymphoma Related Stories Policy / Pricing US generic tariff reprieve on the rocks as Trump proposes 100% rate in 2028 pharminent July 22, 2026 Policy / Pricing UK commits to pharma IP protection in Swiss trade deal pharminent July 16, 2026 Policy / Pricing Germany approves healthcare costs overhaul despite significant pharma opposition pharminent July 13, 2026
